These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
425 related articles for article (PubMed ID: 26995961)
1. [NEGATIVE REGULATORS OF TUMOR SUPPRESSOR P53 IN THE CONTEXT OF ANTICANCER THERAPY]. Shuvalov OY; Fedorova OA; Petukhov AV; Daks AA; Vasilieva EA; Grigorieva TA; Ivanov GS; Barlev NA Tsitologiia; 2015; 57(12):847-54. PubMed ID: 26995961 [TBL] [Abstract][Full Text] [Related]
2. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Toledo F; Wahl GM Nat Rev Cancer; 2006 Dec; 6(12):909-23. PubMed ID: 17128209 [TBL] [Abstract][Full Text] [Related]
3. MDM2 and MDM4: p53 regulators as targets in anticancer therapy. Toledo F; Wahl GM Int J Biochem Cell Biol; 2007; 39(7-8):1476-82. PubMed ID: 17499002 [TBL] [Abstract][Full Text] [Related]
4. Interplay between MDM2, MDMX, Pirh2 and COP1: the negative regulators of p53. Wang L; He G; Zhang P; Wang X; Jiang M; Yu L Mol Biol Rep; 2011 Jan; 38(1):229-36. PubMed ID: 20333547 [TBL] [Abstract][Full Text] [Related]
5. MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer. Tisato V; Voltan R; Gonelli A; Secchiero P; Zauli G J Hematol Oncol; 2017 Jul; 10(1):133. PubMed ID: 28673313 [TBL] [Abstract][Full Text] [Related]
6. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation. Xia M; Knezevic D; Tovar C; Huang B; Heimbrook DC; Vassilev LT Cell Cycle; 2008 Jun; 7(11):1604-12. PubMed ID: 18520179 [TBL] [Abstract][Full Text] [Related]
7. Functional analysis and consequences of Mdm2 E3 ligase inhibition in human tumor cells. Wade M; Li YC; Matani AS; Braun SM; Milanesi F; Rodewald LW; Wahl GM Oncogene; 2012 Nov; 31(45):4789-97. PubMed ID: 22266850 [TBL] [Abstract][Full Text] [Related]
8. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Shangary S; Wang S Annu Rev Pharmacol Toxicol; 2009; 49():223-41. PubMed ID: 18834305 [TBL] [Abstract][Full Text] [Related]
9. Induction of p53 expression and apoptosis by a recombinant dual-target MDM2/MDMX inhibitory protein in wild-type p53 breast cancer cells. Geng QQ; Dong DF; Chen NZ; Wu YY; Li EX; Wang J; Wang SM Int J Oncol; 2013 Dec; 43(6):1935-42. PubMed ID: 24126697 [TBL] [Abstract][Full Text] [Related]
10. Discovery, synthesis, and biological evaluation of orally active pyrrolidone derivatives as novel inhibitors of p53-MDM2 protein-protein interaction. Zhuang C; Miao Z; Zhu L; Dong G; Guo Z; Wang S; Zhang Y; Wu Y; Yao J; Sheng C; Zhang W J Med Chem; 2012 Nov; 55(22):9630-42. PubMed ID: 23046248 [TBL] [Abstract][Full Text] [Related]
11. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX. Hu B; Gilkes DM; Chen J Cancer Res; 2007 Sep; 67(18):8810-7. PubMed ID: 17875722 [TBL] [Abstract][Full Text] [Related]
12. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Tovar C; Rosinski J; Filipovic Z; Higgins B; Kolinsky K; Hilton H; Zhao X; Vu BT; Qing W; Packman K; Myklebost O; Heimbrook DC; Vassilev LT Proc Natl Acad Sci U S A; 2006 Feb; 103(6):1888-93. PubMed ID: 16443686 [TBL] [Abstract][Full Text] [Related]
13. Blockade of Hsp90 by 17AAG antagonizes MDMX and synergizes with Nutlin to induce p53-mediated apoptosis in solid tumors. Vaseva AV; Yallowitz AR; Marchenko ND; Xu S; Moll UM Cell Death Dis; 2011 May; 2(5):e156. PubMed ID: 21562588 [TBL] [Abstract][Full Text] [Related]
14. Novel simplified yeast-based assays of regulators of p53-MDMX interaction and p53 transcriptional activity. Leão M; Gomes S; Soares J; Bessa C; Maciel C; Ciribilli Y; Pereira C; Inga A; Saraiva L FEBS J; 2013 Dec; 280(24):6498-507. PubMed ID: 24119020 [TBL] [Abstract][Full Text] [Related]
15. When the guardian sleeps: Reactivation of the p53 pathway in cancer. Merkel O; Taylor N; Prutsch N; Staber PB; Moriggl R; Turner SD; Kenner L Mutat Res Rev Mutat Res; 2017 Jul; 773():1-13. PubMed ID: 28927521 [TBL] [Abstract][Full Text] [Related]
16. Affinity-based screening of MDM2/MDMX-p53 interaction inhibitors by chemical array: identification of novel peptidic inhibitors. Noguchi T; Oishi S; Honda K; Kondoh Y; Saito T; Kubo T; Kaneda M; Ohno H; Osada H; Fujii N Bioorg Med Chem Lett; 2013 Jul; 23(13):3802-5. PubMed ID: 23726030 [TBL] [Abstract][Full Text] [Related]
17. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties. Soares J; Espadinha M; Raimundo L; Ramos H; Gomes AS; Gomes S; Loureiro JB; Inga A; Reis F; Gomes C; Santos MMM; Saraiva L Mol Oncol; 2017 Jun; 11(6):612-627. PubMed ID: 28296148 [TBL] [Abstract][Full Text] [Related]
18. Reactivation of p53: from peptides to small molecules. Brown CJ; Cheok CF; Verma CS; Lane DP Trends Pharmacol Sci; 2011 Jan; 32(1):53-62. PubMed ID: 21145600 [TBL] [Abstract][Full Text] [Related]
19. Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4. Marine JC; Francoz S; Maetens M; Wahl G; Toledo F; Lozano G Cell Death Differ; 2006 Jun; 13(6):927-34. PubMed ID: 16543935 [No Abstract] [Full Text] [Related]
20. In vitro and in silico studies of MDM2/MDMX isoforms predict Nutlin-3A sensitivity in well/de-differentiated liposarcomas. Bozzi F; Conca E; Laurini E; Posocco P; Lo Sardo A; Jocollè G; Sanfilippo R; Gronchi A; Perrone F; Tamborini E; Pelosi G; Pierotti MA; Maestro R; Pricl S; Pilotti S Lab Invest; 2013 Nov; 93(11):1232-40. PubMed ID: 24018792 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]